Methods of treatment using sterculic acid

• US 8,993,626 B2
• Filed: 06/24/2011
• Issued: 03/31/2015
• Est. Priority Date: 06/25/2010
• Status: Active Grant

• Current Assignee: United States Department Of Health And Human Services
• Original Assignee: United States Department Of Health And Human Services
• Inventors: Rodriguez, Ignacio R., Huang, Jiahn-Dar, Amaral, Juan A., Lee, Jung Wha, Samuel, William, Larrayoz, Ignacio Marcos
• Primary Examiner(s): Kim, Jennifer M
• Application Number:
  US13/805,429
• Publication Number:
  US 20130143966A1
• Time in Patent Office: 1,376 Days
• Field of Search: 514/559
• US Class Current: 514/559
• CPC Class Codes: A61K 31/201 having one or two double bonds, e.g. oleic, linoleic acids
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The use of sterculic acid, and the pharmaceutically acceptable salt forms thereof, described for the treatment of inflammation, in particular, 7-ketocholesterol induced inflammation, 7-ketocholesterol toxicity, and unregulated angiogenesis.

Claims

1. A method of treating age-related macular degeneration comprising:

administering to a patient a therapeutically effective amount of sterculic acid or a pharmaceutically acceptable salt form thereof.

2. The method according to claim 1, wherein the patient is administered a therapeutically effective amount of sterculic acid sufficient to inhibit inflammation induced by 7-ketocholesterol.

3. The method according to claim 1, wherein the patient is administered a therapeutically effective amount of sterculic acid sufficient to inhibit inflammation, cytotoxicity, and/or unregulated angiogenesis induced by 7-ketocholesterol.

4. The method according to claim 1, wherein the patient is administered a therapeutically effective amount of sterculic acid sufficient to inhibit cytotoxicity induced by 7-ketocholesterol.

5. The method according to claim 1, wherein the patient is administered a therapeutically effective amount of sterculic acid sufficient to inhibit unregulated angiogenesis induced by 7-ketocholesterol.

6. The method according to claim 1, wherein the patient is administered a therapeutically effective amount of sterculic acid sufficient to inhibit endothelial cell migration.

7. The method according to claim 1, wherein the age-related macular degeneration is wet age-related macular degeneration.

8. The method according to claim 1, wherein the sterculic acid or pharmaceutically acceptable salt form thereof is administered to the eye of the patient.

9. The method according to claim 1, wherein the sterculic acid or pharmaceutically acceptable salt form thereof is administered one to four times daily.

10. The method according to claim 1, comprising administering a pharmaceutically acceptable salt form of sterculic acid.